Association of chrogranin A (CHGA) genetic polymorphism with patients with thyroid câncer

Authors

  • Izabel Cristina Rodrigues da Silva
  • Bruna Rodrigues Gontijo
  • Isabella Maria Leite e Silva
  • Isabella Possatti
  • Caroline Ferreira Fratelli
  • Ligia Canongia de Abreu Cardoso Duarte
  • Rafael Martins de Morais
  • Jamila Reis de Oliveira

Keywords:

Chromogranin A, Genetic Polymorphism, Neoplasms of the Thyroid Gland

Abstract

Objective: To describe the presence of polymorphism of the codante region of the CHGA Glu264Asp gene and to associate it with the clinical characteristics of the disease. Method: This is a cross-sectional, descriptive and case-control study to investigate chga glu264Asp polymorphism through blood samples from 53 individuals, consisting of 23 patients of both sexes who underwent thyroidectomy and underwent treatment with the Radiopharmaceutical Sodium Iodide (I131). Pcr-RFLP technique was used for genotyping. The significance level of 5% was adopted. Results: There was a statistically significant difference in the allelic distribution between individuals with papillary thyroid cancer and healthy individuals. With everything, the presence of the G alllet is a risk factor for papillary thyroid cancer. A correlation was observed between the GG genotype and the increased level of TSH in patients with this pathology. Conclusion: It was shown that the wild allomay be a risk factor for the development of the thyroid neoplasm of the papilar type. As it is a disease of multifactorial etiology, further studies in different populations are needed to better understand the disease.

References

Vecchia CL, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: A global overview. International Journal of Cancer. 2014 10;136(9):2187 – 2195.

Jung K, Won Y, Kong H, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer research and treatment: official journal of Korean Cancer Association. 2018 04;50(2):303 – 303.

Lim H, Devesa SS, Sosa JÁ, Check D. Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017 4;317: 1338 – 1348

BRASIL. Ministério da Saúde - Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. Estimativa 2018: Incidência de Câncer no Brasil. Rev. Brasileira.De.Cancerologia [Internet]. 30º de março de 2018 [citado 18º de novembro de 2019];64(1):119-20. Disponível em: https://rbc.inca.gov.br/revista/index.php/revista/article/view/115

Sanabria A, Kowalski LP, Shah JP, Nixon IJ, Angelos P, Williams MD, et al. Growing incidence of thyroid carcinoma in recent years: Factors underlying overdiagnosis. Head & neck. 2017 12;40:855 – 866.

Kitahara CM, Schneider AB, Brenner AV. Thyroid cancer. Cancer epidemiology and prevention. 2018;4:839– 860.

Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. American health & drug benefits. 2015 5;8:30 – 40.

Broedbaek K, Hilsted L. Chromogranin A as biomarker in diabetes. Biomarkers in medicine. 2016 9;10:1181 – 1189.

Gut P, Czarnywojtek A, Fischbach J, B ˛aczyk M, Ziemnicka K, Wrotkowska E, et al. Chromogranin A unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Archives of medical science : AMS. 2016 3;12:1 – 9.

D’amico MA, Ghinassi B, Izzicupo P, Manzoli L, Baldassarre AD. Biological function and clinical relevance of chromogranin A and derived peptides. Endocrine connections. 2014 3;3:R45 – 54.

NCBI et al. CHGA chromogranin A [ Homo sapiens (human)] p. Online. Disponivel em: https://www.ncbi.nlm.nih.gov/gene/1113 . Acesso em: 19/11/2019.

Bottoni P, Michele TD, Scatena R. A Critical Approach to Clinical Biochemistry of Chromogranin A. Advances in experimental medicine and biology. 2015 11;867:317 – 23.

Ma Z, Tsuchiya N, Yuasa T, Huang M, Obara T, Narita S. et al. Clinical Significance of polymorphism and expression of chromogranin a and endothelin-1 in prostate cancer. The journal of urology. 2010 7;184: 1182-8.

Mayrhofer BF, Santos C, Cristine G, Montani G, Mazzo I. Utilização dos Hormônios Calcitonina,Catecolaminas E Tireoglobulina Como Marcadores Tumorais: Uma Revisão Bibliográfica. Caderno Saúde e Desenvolvimento. 2017 abr/jul;11(6):59 – 69.

Wu C, Wang L, Chen W, Zou S, Yang A. Associations between body mass index and lymph node metastases of patients with papillary thyroid cancer: A retrospective study. Medicine. 2017 3;96:e6202 –.

de Souza LL, Guedes EP, Teixeira PFDS, Moreira RO, Godoy-Matos AF, Vaisman M. Serum TSH levels are associated with cardiovascular risk factors in overweight and obese adolescents. Jornal de pediatria. 2016 6;92:532 – 8.

Gursoy A. Rising thyroid cancer incidence in the world might be related to insulin resistance. Medical hypotheses. 2009 9;74:35 – 6.

Bétry C, Challan-Belval MA, Bernard A, Charrié A, Drai J, Laville M, et al. Increased TSH in obesity: Evidence for a BMI-independent association with leptin. Diabetes & metabolism. 2014 12;41:248 – 51.

Michèled’Herbomez, Bauters C, Cortet-Rudelli C, Dewailly D, DoCao C, Wémeau J. Biomarqueurs em endocrinologie. La Presse Médicale. 2014 January;43(1):40– 56.

Louthan O. Chromogranin a in physiology and oncology. Folia biologica. 2011 11;57:173 – 81.

de Moraes Mosca L, da Silva CA, Yoon HS, Aisawa RK, Araújo Filho VJF, Matos LL, et al. The association of serum TSH with the risk of well-differentiated thyroid cancer and its relation with disease aggressiveness. Rev bras cir cabeça pescoço. 2014 jul a set;43(3):127 – 131.

Bueno F, Falcone MGG, Peñaloza MA, Abelleira E, Pitoia F. Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer. Endocrine. 2019 10;.

Prado Júnior LM, Marino FM, Prado LM, Mosci K, Navarrete B, Agrizzi L, et al. Análise epidemiológica de portadores de câncer diferenciado de tireóide tratados com iodoterapia. Revista de Medicina e Saúde de Brasília. 2012 Out;1(3):131 – 136.

Downloads

Published

2023-01-15

How to Cite

Silva, I. C. R. da, Gontijo, B. R., Silva, I. M. L. e, Possatti, I., Fratelli, C. F., Duarte, L. C. de A. C., … Oliveira, J. R. de. (2023). Association of chrogranin A (CHGA) genetic polymorphism with patients with thyroid câncer. Revista De Divulgação Científica Sena Aires, 11(4), 630–639. Retrieved from https://rdcsa.emnuvens.com.br/revista/article/view/220

Issue

Vol. 11 No. 4 (2022): REVISA

Section

Original Paper

License

Copyright (c) 2024 Revista de Divulgação Científica Sena Aires

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  • Atribuição — Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.

  • Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.